Twist Bioscience (NASDAQ:TWST) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Twist Bioscience (NASDAQ:TWST) had its target price raised by research analysts at JPMorgan Chase & Co. from $35.00 to $40.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential downside of 25.46% from the company’s current price.

Several other brokerages have also issued reports on TWST. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Scotiabank increased their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Price Performance

Shares of TWST opened at $53.66 on Tuesday. The company has a market capitalization of $3.19 billion, a PE ratio of -14.91 and a beta of 1.87. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The company’s fifty day moving average price is $48.74 and its 200 day moving average price is $46.27.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.75) earnings per share. Analysts anticipate that Twist Bioscience will post -2.27 earnings per share for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This represents a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 5,200 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares of the company’s stock, valued at $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,002 shares of company stock worth $2,851,681. Insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter worth $34,000. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. Signaturefd LLC boosted its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. US Bancorp DE increased its stake in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the third quarter worth approximately $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.